CEO Thomas Feldthus describes the challenge of making ion channel medicines selective enough to avoid unwanted side effects. He walks us through the Jazz and Acadia partnership, and highlights three other internally developed programs.
View all episodes
By BiotechTV
5
44 ratings
CEO Thomas Feldthus describes the challenge of making ion channel medicines selective enough to avoid unwanted side effects. He walks us through the Jazz and Acadia partnership, and highlights three other internally developed programs.
30,626 Listeners
1,863 Listeners
1,085 Listeners
325 Listeners
6,059 Listeners
60 Listeners
9,840 Listeners
86 Listeners
34 Listeners
19 Listeners
260 Listeners
497 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners